EA201291004A1 - Пептиды ect2 и включающие их вакцины - Google Patents
Пептиды ect2 и включающие их вакциныInfo
- Publication number
- EA201291004A1 EA201291004A1 EA201291004A EA201291004A EA201291004A1 EA 201291004 A1 EA201291004 A1 EA 201291004A1 EA 201291004 A EA201291004 A EA 201291004A EA 201291004 A EA201291004 A EA 201291004A EA 201291004 A1 EA201291004 A1 EA 201291004A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- peptides
- nucleic acids
- aforementioned
- substances
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 101000817237 Homo sapiens Protein ECT2 Proteins 0.000 title 1
- 102100040437 Protein ECT2 Human genes 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 206010041067 Small cell lung cancer Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000011224 anti-cancer immunotherapy Methods 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Выделенные пептиды и их фрагменты, полученные из SEQ ID NO: 42, которые связываются с HLA-антигеном и индуцируют цитотоксические Т-лимфоциты (ЦТЛ), и которые, таким образом, подходят для применения в контексте противораковой иммунотерапии, более конкретно, в виде противораковых вакцин, описанных в данном документе. Пептиды по изобретению охватывают как вышеупомянутые аминокислотные последовательности, так и их модифицированные варианты, в которых одна, две или несколько аминокислот заменены, делетированы, вставлены или добавлены, при условии, что такие модифицированные варианты сохраняют необходимое связывание с HLA и/или способность индуцирования ЦТЛ, присущие исходным последовательностям. Дополнительно предлагаются нуклеиновые кислоты, кодирующие любые из вышеупомянутых пептидов, а также предлагаются фармацевтические агенты, вещества и/или композиции, которые включают или содержат любые из вышеупомянутых пептидов или нуклеиновых кислот. Пептиды, нуклеиновые кислоты, фармацевтические агенты, вещества и композиции по настоящему изобретению находят конкретное применение в лечении раковых и опухолевых заболеваний, включающих, например, рак мочевого пузыря, рак груди, рак шейки матки, холангиогенный рак, CML, колоректальный рак, рак пищевода, NSCLC, лимфому, рак поджелудочной железы, рак предстательной железы, светлоклеточный рак и SCLC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32057710P | 2010-04-02 | 2010-04-02 | |
| PCT/JP2011/001909 WO2011122022A1 (en) | 2010-04-02 | 2011-03-30 | Ect2 peptides and vaccines including the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201291004A1 true EA201291004A1 (ru) | 2013-04-30 |
| EA027940B1 EA027940B1 (ru) | 2017-09-29 |
Family
ID=44711777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201291004A EA027940B1 (ru) | 2010-04-02 | 2011-03-30 | Пептиды, обладающие способностью индуцировать цитотоксические т-лимфоциты, и их применение |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8951975B2 (ru) |
| EP (1) | EP2553096B1 (ru) |
| JP (1) | JP5816965B2 (ru) |
| KR (1) | KR101863557B1 (ru) |
| CN (1) | CN102939379B (ru) |
| AR (1) | AR081065A1 (ru) |
| AU (1) | AU2011233401B2 (ru) |
| BR (1) | BR112012024997B1 (ru) |
| CA (1) | CA2795318C (ru) |
| CO (1) | CO6571869A2 (ru) |
| DK (1) | DK2553096T3 (ru) |
| EA (1) | EA027940B1 (ru) |
| ES (1) | ES2655437T3 (ru) |
| IL (1) | IL222057A (ru) |
| MX (1) | MX342000B (ru) |
| NZ (1) | NZ603379A (ru) |
| SG (1) | SG184165A1 (ru) |
| TW (2) | TWI538685B (ru) |
| WO (1) | WO2011122022A1 (ru) |
| ZA (1) | ZA201207342B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| MY198087A (en) | 2015-10-05 | 2023-07-31 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| CA2225553A1 (en) | 1995-08-03 | 1997-02-20 | Rijksuniversiteit Te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6294378B1 (en) | 1996-07-26 | 2001-09-25 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| US7393663B2 (en) * | 1997-08-01 | 2008-07-01 | Serono Genetics Institute S.A. | Expressed sequence tags and encoded human proteins |
| US20030013649A1 (en) | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| AU2002211665B2 (en) * | 2000-10-12 | 2005-10-20 | Exelixis, Inc. | Human Ect2 and methods of use |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7227007B2 (en) * | 2000-12-28 | 2007-06-05 | Asahi Kasei Pharma Corporation | NF-κB activating gene |
| DK2336167T3 (da) | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi |
| AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
| US20030092616A1 (en) | 2001-05-25 | 2003-05-15 | Akio Matsuda | STAT6 activation gene |
| WO2002096943A1 (en) * | 2001-05-25 | 2002-12-05 | Asahi Kasei Kabushiki Kaisha | Stat6-activating genes |
| WO2002099062A2 (en) | 2001-06-04 | 2002-12-12 | Curagen Corporation | Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| JP2005506833A (ja) * | 2001-06-04 | 2005-03-10 | キュラジェン コーポレイション | 抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法 |
| CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP4614952B2 (ja) | 2003-08-20 | 2011-01-19 | オンコセラピー・サイエンス株式会社 | 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２） |
| WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| EP2311983A1 (en) | 2005-02-10 | 2011-04-20 | Oncotherapy Science, Inc. | Method of treating bladder cancer using siRNA |
| EP1907581A2 (en) | 2005-07-27 | 2008-04-09 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| EP2311986B1 (en) | 2005-07-27 | 2015-04-15 | Oncotherapy Science, Inc. | Method of diagnosing esophageal cancer |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| CN101432022A (zh) * | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| CN101589059A (zh) * | 2006-10-20 | 2009-11-25 | 株式会社未来创药研究所 | 包含抗hb-egf抗体作为活性成分的药物组合物 |
| WO2008047925A1 (fr) | 2006-10-20 | 2008-04-24 | Forerunner Pharma Research Co., Ltd. | Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif |
| TWI438207B (zh) * | 2007-02-21 | 2014-05-21 | Oncotherapy Science Inc | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP2105511A1 (en) | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung |
| JP2011528221A (ja) | 2008-07-16 | 2011-11-17 | オンコセラピー・サイエンス株式会社 | 肺癌および食道癌に関する治療標的および予後指標としてのｅｃｔ２癌遺伝子 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2011
- 2011-03-23 TW TW100109936A patent/TWI538685B/zh not_active IP Right Cessation
- 2011-03-23 TW TW105112382A patent/TW201627003A/zh unknown
- 2011-03-30 NZ NZ603379A patent/NZ603379A/en not_active IP Right Cessation
- 2011-03-30 MX MX2012011385A patent/MX342000B/es active IP Right Grant
- 2011-03-30 WO PCT/JP2011/001909 patent/WO2011122022A1/en active Application Filing
- 2011-03-30 US US13/638,272 patent/US8951975B2/en active Active
- 2011-03-30 BR BR112012024997-5A patent/BR112012024997B1/pt not_active IP Right Cessation
- 2011-03-30 ES ES11762265.4T patent/ES2655437T3/es active Active
- 2011-03-30 CN CN201180027360.5A patent/CN102939379B/zh not_active Expired - Fee Related
- 2011-03-30 EA EA201291004A patent/EA027940B1/ru not_active IP Right Cessation
- 2011-03-30 DK DK11762265.4T patent/DK2553096T3/en active
- 2011-03-30 EP EP11762265.4A patent/EP2553096B1/en active Active
- 2011-03-30 JP JP2012543839A patent/JP5816965B2/ja active Active
- 2011-03-30 SG SG2012069696A patent/SG184165A1/en unknown
- 2011-03-30 KR KR1020127028426A patent/KR101863557B1/ko not_active Expired - Fee Related
- 2011-03-30 AU AU2011233401A patent/AU2011233401B2/en not_active Ceased
- 2011-03-30 CA CA2795318A patent/CA2795318C/en active Active
- 2011-04-01 AR ARP110101103A patent/AR081065A1/es unknown
-
2012
- 2012-09-23 IL IL222057A patent/IL222057A/en active IP Right Grant
- 2012-10-01 ZA ZA2012/07342A patent/ZA201207342B/en unknown
- 2012-10-03 CO CO12173572A patent/CO6571869A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20130095128A1 (en) | 2013-04-18 |
| WO2011122022A1 (en) | 2011-10-06 |
| CN102939379A (zh) | 2013-02-20 |
| EP2553096A1 (en) | 2013-02-06 |
| US8951975B2 (en) | 2015-02-10 |
| JP5816965B2 (ja) | 2015-11-18 |
| EP2553096B1 (en) | 2017-11-22 |
| DK2553096T3 (en) | 2018-01-15 |
| AU2011233401A1 (en) | 2012-10-25 |
| EP2553096A4 (en) | 2013-11-13 |
| MX342000B (es) | 2016-09-09 |
| KR20130033367A (ko) | 2013-04-03 |
| TW201627003A (zh) | 2016-08-01 |
| AR081065A1 (es) | 2012-06-06 |
| CN102939379B (zh) | 2016-08-03 |
| JP2013523082A (ja) | 2013-06-17 |
| CA2795318A1 (en) | 2011-10-06 |
| NZ603379A (en) | 2014-09-26 |
| BR112012024997B1 (pt) | 2022-03-22 |
| CA2795318C (en) | 2018-11-13 |
| ES2655437T3 (es) | 2018-02-20 |
| SG184165A1 (en) | 2012-10-30 |
| CO6571869A2 (es) | 2012-11-30 |
| ZA201207342B (en) | 2013-06-26 |
| MX2012011385A (es) | 2013-12-16 |
| TW201138803A (en) | 2011-11-16 |
| AU2011233401B2 (en) | 2015-03-26 |
| IL222057A (en) | 2017-12-31 |
| BR112012024997A2 (pt) | 2017-05-23 |
| KR101863557B1 (ko) | 2018-06-01 |
| EA027940B1 (ru) | 2017-09-29 |
| TWI538685B (zh) | 2016-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091233A2 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| EA201100586A1 (ru) | Новая иммунотерапия против нескольких видов опухолей, включая нейрональные опухоли и опухоли головного мозга | |
| EA201071297A1 (ru) | Новые и действенные пептиды мнс ii класса, полученные из сурвивина | |
| EA201791519A1 (ru) | Новая иммунотерапия против нейрональных опухолей и опухолей головного мозга | |
| CR20230563A (es) | NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579) | |
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| BR112012025567A2 (pt) | peptídeos de cdca5 e vacinas que incluem os mesmos | |
| MX2014001675A (es) | Peptidos de mphosph1 y vacunas que incluyen los mismos. | |
| PH12014500720A1 (en) | Topk peptides and vaccines including the same | |
| EA201291004A1 (ru) | Пептиды ect2 и включающие их вакцины | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| MX344579B (es) | Peptidos hjurp y vacunas que incluyen los mismos. | |
| MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
| SG10201408245WA (en) | Tmem22 peptides and vaccines including the same | |
| PH12012501935A1 (en) | Ect2 peptides and vaccines including the same | |
| EP2370454A4 (en) | WDRPUH EPITOP PEPTIDES AND VACCINES CONTAINING THEM | |
| TH126648A (th) | Ect2 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |